Pharmacokinetics of the Oral Selective CXCR2 Antagonist AZD5069: A Summary of Eight Phase I Studies in Healthy Volunteers

por Cullberg, Marie, Arfvidsson, Cecilia, Larsson, Bengt, Malmgren, Anna, Mitchell, Patrick, Wählby Hamrén, Ulrika, Wray, Heather
Publicado 2018

Safety, pharmacokinetics and pharmacodynamics of the selective glucocorticoid receptor modulator AZD7594, following inhalation in healthy Japanese volunteers

por Prothon, Susanne, Wählby Hamrén, Ulrika, Tehler, Ulrika, Yoon, Esther, Forsman, Henrik, Arfvidsson, Cecilia, Aggarwal, Ajay, Chen, Yingxue
Publicado 2019

Longitudinal FEV(1) and Exacerbation Risk in COPD: Quantifying the Association Using Joint Modelling

por Zhudenkov, Kirill, Palmér, Robert, Jauhiainen, Alexandra, Helmlinger, Gabriel, Stepanov, Oleg, Peskov, Kirill, Eriksson, Ulf G, Wählby Hamrén, Ulrika
Publicado 2021

Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting,...

por Singh, Dave, Balaguer, Victor, Astbury, Carol, Wählby-Hamrén, Ulrika, Jimenez, Eulalia, Seoane, Beatriz, Villarroel, Cristina, Lei, Alejhandra, Aggarwal, Ajay, Psallidas, Ioannis
Publicado 2020

Navafenterol (AZD8871) in patients with mild asthma: a randomised placebo-controlled phase I study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of si...

por Jimenez, Eulalia, Astbury, Carol, Albayaty, Muna, Wählby-Hamrén, Ulrika, Seoane, Beatriz, Villarroel, Cristina, Pujol, Helena, Bermejo, Maria Jesus, Aggarwal, Ajay, Psallidas, Ioannis
Publicado 2020

Navafenterol (AZD8871) in healthy volunteers: safety, tolerability and pharmacokinetics of multiple ascending doses of this novel inhaled, long-acting, dual-pharmacology bronchodil...

por Balaguer, Victor, Albayaty, Muna, Jimenez, Eulalia, Wählby-Hamrén, Ulrika, Astbury, Carol, Seoane, Beatriz, Malice, Marie-Pierre, Lei, Alejhandra, Aggarwal, Ajay, Psallidas, Ioannis
Publicado 2020

Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants

por Wilkins, Deidre, Yuan, Yuan, Chang, Yue, Aksyuk, Anastasia A., Núñez, Beatriz Seoane, Wählby-Hamrén, Ulrika, Zhang, Tianhui, Abram, Michael E., Leach, Amanda, Villafana, Tonya, Esser, Mark T.
Publicado 2023

The novel bronchodilator navafenterol: a phase 2a, multicentre, randomised, double-blind, placebo-controlled crossover trial in COPD

por Singh, Dave, Beier, Jutta, Astbury, Carol, Belvisi, Maria G., Da Silva, Carla A., Jauhiainen, Alexandra, Jimenez, Eulalia, Lei, Alejhandra, Necander, Sofia, Smith, Jaclyn A., Wählby Hamrén, Ulrika, Xin, Wenjing, Psallidas, Ioannis
Publicado 2022

Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease

por Domachowske, Joseph B, Chang, Yue, Atanasova, Victoria, Cabañas, Fernando, Furuno, Kenji, Nguyen, Kim A, Banu, Irfana, Kubiak, Robert J, Leach, Amanda, Mankad, Vaishali S, Shroff, Manish, Takas, Therese, Villafana, Tonya, Wählby Hamrén, Ulrika
Publicado 2023

Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congeni...

por Simões, Eric A F, Madhi, Shabir A, Muller, William J, Atanasova, Victoria, Bosheva, Miroslava, Cabañas, Fernando, Baca Cots, Manuel, Domachowske, Joseph B, Garcia-Garcia, Maria L, Grantina, Ineta, Nguyen, Kim A, Zar, Heather J, Berglind, Anna, Cummings, Celeste, Griffin, M Pamela, Takas, Therese, Yuan, Yuan, Wählby Hamrén, Ulrika, Leach, Amanda, Villafana, Tonya
Publicado 2023